Licensed indication for risperidone in dementiaBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7337 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7337
- David Phizackerley, deputy editor
- 1Drug and Therapeutics Bulletin, BMJ Evidence Centre, BMA House, London WC1H 9JR, UK
When referring to the licensed indication for risperidone, Corbett and colleagues state: “In Europe, only risperidone is currently licensed for use in dementia and only for up to six weeks in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial